SCHEMBL21290182

SCHEMBL21290182

Clc1ccccc1-c1cnc(-c2ccccc2)cc1-c1ccc(-c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.52
MAP4K4 O95819 2/20 0.45
ADORA1 P30542 2/20 0.44
HPGD P15428 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 1/20 0.44
ADORA2A P29274 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 1/20 0.44
ATM Q13315 1/20 0.44
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
USP7 Q93009 1/20 0.42
DYRK1A Q13627 1/20 0.40
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
SMO Q99835 3/20 0.39
SCN9A Q15858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21289783 1.00 CYP2A6 (0.52) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL25100959 0.95 CYP2A6 (0.47) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL23487747 0.93 L3MBTL1 (0.45) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL23487744 0.86 ALOX5AP (0.44) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL21289780 0.84 LDHA (0.43) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL24291892 0.84 RXRA (0.41) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL25100524 0.84 KIF11 (0.41) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL21290375 0.83 ALOX5AP (0.40) CYP2A6MAP4K4ADORA1HPGDKMT2A
SCHEMBL21290222 0.83 ROS1 (0.43) MAP4K4ADORA1HPGDKMT2AL3MBTL1
SCHEMBL21290223 0.83 L3MBTL1 (0.41) CYP2A6MAP4K4ADORA1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752512-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2023-03-01 EP disclosed
US-20230056324-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2023-02-23 US disclosed
US-20220098477-A1 MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY UDC IRELAND LIMITED (IE) 2022-03-31 US disclosed
WO-2019158453-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2019-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056324-A1 METAL COMPLEXES MCU, IMMT, SOD1 CYP2A6 4118/4885MAP4K4 4234/4885ADORA1 4716/4885
US-20220098477-A1 MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY ICOSLG, CCL11, CCR3 CYP2A6 4171/4885MAP4K4 1617/4885ADORA1 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.